Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Reuters2d
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...
Hosted on MSN2d
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has ...
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Yahoo Finance8h
Novavax Third Quarter 2024 Earnings: Beats Expectations
Revenue: US$84.5m (down 55% from 3Q 2023). Net loss: US$121.3m (loss narrowed by 7.2% from 3Q 2023). US$0.76 loss per share ...
Novavax falls after guidance cut on lower vaccine sales
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...
BioPharma Dive3d
FDA lifts pause on Novavax flu vaccine trials
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
Spotlight on Novavax: Analyzing the Surge in Options Activity
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.